R J Boado

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport
    Ruben J Boado
    Department of Medicine, UCLA, Los Angeles, CA 90024, USA
    Mol Genet Metab 83:306-11. 2004
  2. ncbi request reprint Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Neurosci Res 40:337-42. 2001
  3. ncbi request reprint Antisense-mediated down-regulation of the human huntingtin gene
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, California, USA
    J Pharmacol Exp Ther 295:239-43. 2000
  4. pmc Selective expression of the large neutral amino acid transporter at the blood-brain barrier
    R J Boado
    Department of Medicine, University of California School of Medicine, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 96:12079-84. 1999
  5. ncbi request reprint Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234
    Ruben J Boado
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA
    J Neurochem 84:1322-31. 2003
  6. ncbi request reprint Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells
    Ruben J Boado
    Department of Medicine, UCLA School of Medicine, Warren Hall 13 164, 900 Veteran Avenue, Los Angeles, CA 90024, USA
    J Neurochem 85:1037-42. 2003
  7. ncbi request reprint Blood-brain barrier transport of non-viral gene and RNAi therapeutics
    Ruben J Boado
    Department of Medicine, UCLA Warren Hall 13 164, 900 Veteran Ave, Los Angeles, CA, 90024, USA
    Pharm Res 24:1772-87. 2007
  8. ncbi request reprint Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein
    Ruben J Boado
    Department of Medicine, University of California at Los Angeles, CA 90024, USA
    Pediatr Res 55:557-60. 2004
  9. ncbi request reprint Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1
    Ruben J Boado
    Department of Medicine, UCLA Warren Hall 13 164, 900 Veteran Ave, Los Angeles, CA 90024, USA
    Biochim Biophys Acta 1715:104-10. 2005
  10. pmc RNA interference and nonviral targeted gene therapy of experimental brain cancer
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    NeuroRx 2:139-50. 2005

Collaborators

Detail Information

Publications74

  1. ncbi request reprint Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport
    Ruben J Boado
    Department of Medicine, UCLA, Los Angeles, CA 90024, USA
    Mol Genet Metab 83:306-11. 2004
    ..These studies demonstrate that the only known SNP in the open reading frame of human LAT1 has no effect on the kinetics of large neutral amino acid transport via this carrier...
  2. ncbi request reprint Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Neurosci Res 40:337-42. 2001
    ....
  3. ncbi request reprint Antisense-mediated down-regulation of the human huntingtin gene
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, California, USA
    J Pharmacol Exp Ther 295:239-43. 2000
    ..In summary, a series of putative AS candidates were screened for down-regulation of the huntingtin gene, and an ODN molecule directed to the methionine initiation codon was identified with maximum AS effects...
  4. pmc Selective expression of the large neutral amino acid transporter at the blood-brain barrier
    R J Boado
    Department of Medicine, University of California School of Medicine, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 96:12079-84. 1999
    ....
  5. ncbi request reprint Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234
    Ruben J Boado
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA
    J Neurochem 84:1322-31. 2003
    ..These studies show that marked changes in the affinity and capacity of the LAT1 are caused by single nucleotide polymorphisms and that phenotype can be restored with a double mutation...
  6. ncbi request reprint Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells
    Ruben J Boado
    Department of Medicine, UCLA School of Medicine, Warren Hall 13 164, 900 Veteran Avenue, Los Angeles, CA 90024, USA
    J Neurochem 85:1037-42. 2003
    ..These studies are consistent with post-transcriptional de-stabilization of the LAT1 large neutral amino acid transporter in hypoxia...
  7. ncbi request reprint Blood-brain barrier transport of non-viral gene and RNAi therapeutics
    Ruben J Boado
    Department of Medicine, UCLA Warren Hall 13 164, 900 Veteran Ave, Los Angeles, CA, 90024, USA
    Pharm Res 24:1772-87. 2007
    ..The present review presents an overview of the THL technology and its current application to gene therapy and RNAi, including experimental models of Parkinson's disease and brain tumors...
  8. ncbi request reprint Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein
    Ruben J Boado
    Department of Medicine, University of California at Los Angeles, CA 90024, USA
    Pediatr Res 55:557-60. 2004
    ..The dissociation between LAT1 protein and mRNA levels in development is consistent with posttranscriptional regulation of BBB LAT1 gene expression...
  9. ncbi request reprint Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1
    Ruben J Boado
    Department of Medicine, UCLA Warren Hall 13 164, 900 Veteran Ave, Los Angeles, CA 90024, USA
    Biochim Biophys Acta 1715:104-10. 2005
    ..These studies show that the Cys439 residue of LAT1 plays a significant role in either folding or insertion of the transporter protein in the plasma membrane...
  10. pmc RNA interference and nonviral targeted gene therapy of experimental brain cancer
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    NeuroRx 2:139-50. 2005
    ..The accessibility to chimeric and/or humanized mAbs directed to human BBB and brain cell specific-receptors may accelerate the application of this technology to the treatment of human tumors...
  11. ncbi request reprint Cloning and expression in Pichia pastoris of a genetically engineered single chain antibody against the rat transferrin receptor
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, CA 90095 1682, USA
    J Drug Target 8:403-12. 2000
    ..The present investigation suggests that this expression system may be useful for the production of anti-receptor single chain antibodies that can be used as brain drug delivery vectors...
  12. ncbi request reprint Selective Lutheran glycoprotein gene expression at the blood-brain barrier in normal brain and in human brain tumors
    R J Boado
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    J Cereb Blood Flow Metab 20:1096-102. 2000
    ....
  13. ncbi request reprint Differential kinetics of transport of 2',3'-dideoxyinosine and adenosine via concentrative Na+ nucleoside transporter CNT2 cloned from rat blood-brain barrier
    J Y Li
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    J Pharmacol Exp Ther 299:735-40. 2001
    ..These studies provide evidence for asymmetric transport sites on rat CNT2, where 2',3'-dideoxyinosine and thymidine compete selectively at a low Vmax site on the transporter, whereas adenosine is transported at a high Vmax site...
  14. ncbi request reprint Receptor-mediated delivery of an antisense gene to human brain cancer cells
    Yun Zhang
    Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90024, USA
    J Gene Med 4:183-94. 2002
    ..High-grade brain gliomas overexpress the epidermal growth factor receptor (EGFR) and EGFR antisense gene therapy could reduce the growth of EGFR-dependent gliomas...
  15. ncbi request reprint Brain-derived peptides increase blood-brain barrier GLUT1 glucose transporter gene expression via mRNA stabilization
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Neurosci Lett 255:147-50. 1998
    ..In conclusion, data presented here demonstrate that factors in CI increase BBB-GLUT1 transcript stability, and that this is associated with an induction of BBB-GLUT1 gene expression in brain endothelial cultured cells...
  16. ncbi request reprint Blood-brain barrier genomics
    J Y Li
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095 1682, USA
    J Cereb Blood Flow Metab 21:61-8. 2001
    ..Knowledge of tissue-specific gene expression at the BBB could lead to new targets for brain drug delivery and could elucidate mechanisms of brain pathology at the microvascular level...
  17. ncbi request reprint Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes
    N Shi
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA
    Pharm Res 18:1091-5. 2001
    ..The liposomes are formulated to target specific receptor systems that enable receptor-mediated endocytosis of the complex into cells in vivo. This approach allows for non-invasive, non-viral gene therapy of the brain...
  18. pmc Brain-specific expression of an exogenous gene after i.v. administration
    N Shi
    Department of Medicine, University of California School of Medicine, Los Angeles, CA 90024, USA
    Proc Natl Acad Sci U S A 98:12754-9. 2001
    ..These studies indicate that tissue-specific gene expression in brain is possible after the i.v. administration of a nonviral vector with the combined use of gene targeting technology and tissue-specific gene promoters...
  19. ncbi request reprint Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Neurosci Lett 220:53-6. 1996
    ..The data presented here demonstrate that C1 increases BBB-GLUT1 gene expression in ECL cells through a mechanism that appears to be independent of activation of PKC...
  20. ncbi request reprint In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides
    R J Boado
    Department of Medicine, and Brain Research Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Neurosci Res 34:217-24. 1999
    ..Data presented here demonstrate that the in vivo administration of Cl increases the transport of glucose from blood to brain via BBB-GLUT1 gene expression...
  21. ncbi request reprint Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na+ nucleoside cotransporter CNT2
    J Y Li
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA
    J Cereb Blood Flow Metab 21:929-36. 2001
    ..These results suggest that BBB adenosine transport in vivo is mediated by CNT2, which would make CNT2 one of the few known sodium-dependent cotransporters that mediate substrate transport across the BBB in the blood to brain direction...
  22. ncbi request reprint Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology
    Chun Fang Xia
    Department of Medicine, UCLA, Warren Hall 13 164, 900 Veteran Ave, Los Angeles, California, USA
    Pharm Res 24:2309-16. 2007
    ....
  23. ncbi request reprint Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, California 90095, USA
    J Pharm Sci 87:1308-15. 1998
    ..The overall experimental evidence suggests that PNA-OX26-SA conjugates represent optimal antisense molecules for drug delivery to the brain...
  24. ncbi request reprint Amplification of gene expression using both 5'- and 3'-untranslated regions of GLUT1 glucose transporter mRNA
    R J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Brain Res Mol Brain Res 63:371-4. 1999
    ..Data presented here demonstrate that cis-regulatory elements located at both the 5'- and 3'-UTR of GLUT1 mRNA increase expression of a reporter gene in an independent manner...
  25. ncbi request reprint In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats
    Yun Zhang
    Department of Medicine, UCLA, Los Angeles, CA 90024, USA
    J Gene Med 5:1039-45. 2003
    ..The limiting factor in developing RNAi therapeutics in mammals is the gene delivery system...
  26. ncbi request reprint Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer
    Yun Zhang
    Departments of Medicine and Neurology, University of California Los Angeles, Los Angeles, California 90024, USA
    Clin Cancer Res 10:3667-77. 2004
    ..The present study was designed to prolong survival in mice with intracranial human brain cancer with the weekly i.v. injection of nonviral gene therapy causing RNA interference (RNAi) of EGFR gene expression...
  27. ncbi request reprint The 5'-untranslated region of GLUT1 glucose transporter mRNA causes differential regulation of the translational rate in plant and animal systems
    R J Boado
    Department of Medicine, CCLA School of Medicine 90095, USA
    Comp Biochem Physiol B Biochem Mol Biol 118:309-12. 1997
    ....
  28. pmc Brain-penetrating tumor necrosis factor decoy receptor in the mouse
    Qing Hui Zhou
    Department of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Drug Metab Dispos 39:71-6. 2011
    ..This new IgG-TNFR fusion protein can be tested in mouse models of brain diseases in which TNF╬▒ plays a pathologic role...
  29. ncbi request reprint Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element
    Ruben J Boado
    Department of Medicine and Brain Research Institute, UCLA School of Medicine, Los Angeles, California 90024, USA
    J Neurochem 80:552-4. 2002
    ..Data presented here suggest that the GLUT1 CAE2181-2190 participates in the increase of GLUT1 gene expression in glucose deprivation and hypoxia...
  30. ncbi request reprint Marked enhancement in gene expression by targeting the human insulin receptor
    Yun Zhang
    Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90024, USA
    J Gene Med 5:157-63. 2003
    ..The liposomes are targeted to cells with receptor-specific targeting ligands such as receptor-specific peptidomimetic monoclonal antibodies...
  31. ncbi request reprint Rat blood-brain barrier genomics. II
    Jian Yi Li
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA
    J Cereb Blood Flow Metab 22:1319-26. 2002
    ..Brain vascular genomics, or BBB genomics, allows for an accelerated discovery of the gene families that are differentially expressed at the microvasculature in brain...
  32. ncbi request reprint Subtractive expression cloning reveals high expression of CD46 at the blood-brain barrier
    Eric V Shusta
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA
    J Neuropathol Exp Neurol 61:597-604. 2002
    ..The finding of selective expression of CD46 at the BBB is consistent with an important role played by the microvasculature in the immune surveillance of the brain...
  33. ncbi request reprint hnRNP A2 and hnRNP L bind the 3'UTR of glucose transporter 1 mRNA and exist as a complex in vivo
    B J Hamilton
    Department of Medicine, Dartmouth Medical School, Lebanon, New Hampshire, 03756, USA
    Biochem Biophys Res Commun 261:646-51. 1999
    ..Immunoprecipitation demonstrated that hnRNP A2 and L exist as a complex in vivo. As a result of these and other studies, we conclude that hnRNP A2 and L associate in vivo and independently bind the 3'UTR of Glut1 mRNA...
  34. doi request reprint Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier
    Eric Ka Wai Hui
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    Mol Pharm 6:1536-43. 2009
    ..In conclusion, these studies describe the re-engineering of the TNFR ECD to make this decoy receptor transportable across the human BBB...
  35. doi request reprint Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase
    Jeff Zhiqiang Lu
    ArmaGen Technologies, Inc, Santa Monica, CA 90401, USA
    Bioconjug Chem 21:151-6. 2010
    ..The HIRMAb-IDS fusion protein is a bifunctional IgG-sulfatase fusion protein, which has been specifically engineered for targeted drug delivery across the human BBB...
  36. pmc Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse
    Qing Hui Zhou
    Department of Medicine, University of California, Los Angeles, USA
    Drug Metab Dispos 38:566-72. 2010
    ..The brain uptake results indicate it is possible to achieve therapeutic elevations of GDNF in mouse brain with intravenous administration of the cTfRMAb-GDNF fusion protein...
  37. doi request reprint Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California, USA
    J Pharmacol Exp Ther 333:961-9. 2010
    ..The IgG-EPO fusion protein represents a new class of EPO neurotherapeutics that has been specifically re-engineered to penetrate the human BBB...
  38. ncbi request reprint Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation
    Chun Chu
    Department of Medicine, UCLA, UCLA Warren Hall 13 164, 900 Veteran Avenue, Los Angeles, CA 90024, USA
    Pharm Res 23:1586-90. 2006
    ....
  39. ncbi request reprint Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice
    Chunni Zhu
    Department of Medicine, UCLA, Los Angeles, CA 90024, USA
    J Gene Med 6:906-12. 2004
    ..Adult transgenics' is possible with the acute expression of an exogenous gene that is administered to adult animals, providing the transgene can be effectively delivered to distant sites following an intravenous administration...
  40. ncbi request reprint Vascular genomics of the human brain
    Eric V Shusta
    Departments of Medicine and Surgery Neurosurgery, UCLA School of Medicine, Los Angeles, California 90024, USA
    J Cereb Blood Flow Metab 22:245-52. 2002
    ....
  41. ncbi request reprint Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter
    Yun Zhang
    Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90024, USA
    Hum Gene Ther 15:339-50. 2004
    ..These studies demonstrate that global delivery of exogenous genes to the brain is possible with intravenous nonviral gene transfer, and that ectopic gene expression is eliminated with the use of brain-specific gene promoters...
  42. ncbi request reprint Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism
    Yun Zhang
    Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA 90024, USA
    Hum Gene Ther 14:1-12. 2003
    ..These studies demonstrate that it is possible to normalize brain enzyme activity by intravenous administration and nonviral gene transfer...
  43. ncbi request reprint Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer
    Yun Zhang
    Department of Medicine, UCLA, Los Angeles, CA 90024, USA
    Mol Vis 9:465-72. 2003
    ....
  44. ncbi request reprint Molecular cloning of the bovine blood-brain barrier glucose transporter cDNA and demonstration of phylogenetic conservation of the 5'-untranslated region
    R J Boado
    Department of Medicine, Division of Endocrinology, and Brain Research Institute, UCLA School of Medicine, Los Angeles, California 90024 1682, USA
    Mol Cell Neurosci 1:224-32. 1990
    ..The extensive phylogenetic conservation of the 5'-UTR suggests the GLUT-1 gene may be subject to translational control in the regulation of BBB glucose transport...
  45. pmc Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California, USA
    Drug Metab Dispos 37:2299-304. 2009
    ..The brain uptake parameters show that a systemic dose of the HIR MAb-GDNF fusion protein of 0.2 mg/kg may generate a 10-fold increase in the cerebral concentration of GDNF in the human brain...
  46. ncbi request reprint Blood-brain barrier genomics
    Ruben J Boado
    Department of Medicine, Brain Research Institute, UCLA School of Medicine, Los Angeles, CA, USA
    Methods Mol Med 89:401-18. 2003
  47. pmc Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology
    Chun Fang Xia
    Department of Medicine, UCLA, Los Angeles, California 90024, USA
    Mol Pharm 6:747-51. 2009
    ....
  48. pmc Genetic engineering of IgG-glucuronidase fusion proteins
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, CA, USA
    J Drug Target 18:205-11. 2010
    ..This study illustrates the differential retention of functionality of IgG-enzyme fusion proteins depending on how the fusion protein is engineered...
  49. pmc IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    Mol Pharm 5:1037-43. 2008
    ..In conclusion, human PON1 has been re-engineered as an IgG-organophosphatase fusion protein that penetrates the human BBB...
  50. doi request reprint Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    Bioconjug Chem 19:731-9. 2008
    ..In summary, the HIRMAb-AV fusion protein is a new drug targeting system for humans that can be adapted to monobiotinylated drugs or nucleic acids...
  51. pmc AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys
    Ruben J Boado
    ArmaGen Technologies Inc, Santa Monica, CA 90401, USA
    J Biotechnol 144:135-41. 2009
    ..The safety pharmacology studies provide the basis for future drug development of AGT-181 as a new therapeutic approach to treatment of the brain in Hurler's syndrome...
  52. ncbi request reprint Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter
    Chun Fang Xia
    Department of Medicine, UCLA, Los Angeles, CA, USA
    J Gene Med 10:306-15. 2008
    ..Expression of the transgene is confined to catecholaminergic cells by placement of the GDNF gene under the influence of the rat tyrosine hydroxylase (TH) promoter...
  53. pmc Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation
    Ruben J Boado
    ArmaGen Technologies, Incorporated, Santa Monica, California, USA
    Bioconjug Chem 18:447-55. 2007
    ..This fusion protein is a new antibody-based therapeutic for Alzheimer's disease that is specifically engineered to cross the human blood-brain barrier in both directions...
  54. ncbi request reprint Vascular proteomics and subtractive antibody expression cloning
    Eric V Shusta
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA
    Mol Cell Proteomics 1:75-82. 2002
    ..This subtractive expression cloning methodology provides a new approach to "vascular proteomics" and to the detection of proteins specifically expressed at the microvasculature, including membrane proteins...
  55. pmc Blood-brain barrier genomics and cloning of a novel organic anion transporter
    Chun Chu
    Department of Medicine, UCLA, Los Angeles, California 90024, USA
    J Cereb Blood Flow Metab 28:291-301. 2008
    ..Blood-brain barrier-specific anion transporter type 1 is a novel organic anion transporter that is a sodium-independent exchanger that may participate in the active efflux of iodothyronines and steroid conjugates at the BBB...
  56. ncbi request reprint Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer
    Yun Zhang
    Department of Medicine, UCLA, Warren Hall 13 164, 900 Veteran Ave, Los Angeles, CA 90024, USA
    Pharm Res 25:400-6. 2008
    ....
  57. ncbi request reprint Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes
    Chun Fang Xia
    Department of Medicine, UCLA, Los Angeles, CA 90024, USA
    J Gene Med 9:605-12. 2007
    ..The brain expression of a rat tyrosine hydroxylase (TH) cDNA is compared to the brain expression of a plasmid DNA encoding the 18 kb rat TH gene...
  58. ncbi request reprint Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes
    Yu feng Zhang
    Department of Medicine, UCLA, Los Angeles, CA 90024, USA
    Pharm Res 20:1779-85. 2003
    ..Therefore, the purpose of the present study was to examine for toxic side effects of the chronic weekly intravenous administration of plasmid DNA delivered with a nonviral gene transfer method using pegylated immunoliposomes (PIL)...
  59. ncbi request reprint Enzyme binding-inhibiting assay for iodothyronine 5'-monodeiodinase (5'-MD) and its application to isolation of complementary deoxyribonucleic acid clones for the 5'-MD in rat liver
    R J Boado
    Department of Medicine, University of California School of Medicine, Los Angeles 90024
    Endocrinology 123:1264-73. 1988
    ..Northern blot analysis using clone 23 insert cDNA as the probe showed a hybridization band corresponding to a mRNA approximating 2.8 kilobases.(ABSTRACT TRUNCATED AT 400 WORDS)..
  60. pmc Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier
    Ailing Fu
    Department of Medicine, UCLA, Los Angeles, CA 90024, USA
    Brain Res 1352:208-13. 2010
    ..In conclusion, following fusion of GDNF to a BBB molecular Trojan horse, GDNF trophic effects in brain in experimental PD are observed following intravenous administration...
  61. pmc Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, CA, United States
    J Biotechnol 146:84-91. 2010
    ..IgG-decoy receptor fusion proteins represent a new class of human neurotherapeutics...
  62. ncbi request reprint Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology
    Hwa Jeong Lee
    Department of Medicine, UCLA School of Medicine, 90024, USA
    J Nucl Med 43:948-56. 2002
    ..The current studies describe the production of 16-mer peptide nucleic acid (PNA) that is antisense around the methionine initiation codon of the huntingtin gene of Huntington's disease (HD)...
  63. pmc Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    Mol Pharm 7:237-44. 2010
    ..06 +/- 0.01% ID/g. These studies demonstrate that therapeutic MAbs may be re-engineered as fusion proteins with BBB molecular Trojan horses for targeted delivery across the BBB in vivo...
  64. pmc IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California, USA
    Biotechnol Bioeng 105:627-35. 2010
    ..In conclusion, the HIRMAb-ScFv fusion protein is a new class of antibody-based therapeutic for AD that has been specifically engineered to cross the human BBB...
  65. pmc Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery
    William M Pardridge
    ArmaGen Technologies, Inc, 914 Colorado Ave, Santa Monica, California 90401, USA
    Pharm Res 26:2227-36. 2009
    ..The pharmacokinetics (PK), toxicology, and safety pharmacology of the HIRMAb-GDNF fusion protein were investigated in Rhesus monkeys...
  66. ncbi request reprint Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    Biotechnol Bioeng 96:381-91. 2007
    ..The humanized HIRMAb may be used as a brain drug and gene delivery system for the targeting of large molecule therapeutics across the BBB in humans...
  67. ncbi request reprint Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier
    Ruben J Boado
    ArmaGen Technologies Inc, Santa Monica, California, USA
    Biotechnol Bioeng 97:1376-86. 2007
    ..Neurotrophins, such as BDNF, can be re-formulated to enable these molecules to cross the human BBB, and such fusion proteins represent a new class of human neurotherapeutics...
  68. ncbi request reprint Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    Biotechnol Bioeng 99:475-84. 2008
    ..The HIRMAb-IDUA fusion protein is a new treatment for Hurler's syndrome, which has been specifically engineered to cross the human BBB...
  69. ncbi request reprint GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California, USA
    Biotechnol Bioeng 100:387-96. 2008
    ..001). In conclusion, these studies describe the re-engineering of GDNF, to make this neurotrophin transportable across the human BBB...
  70. pmc Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California, USA
    Biotechnol Bioeng 102:1251-8. 2009
    ....
  71. doi request reprint A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery
    Ruben J Boado
    ArmaGen Technologies, Inc, Santa Monica, California 90401, USA
    Drug News Perspect 21:489-503. 2008
    ....
  72. ncbi request reprint The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature
    Eric V Shusta
    Department of Chemical and Biological Engineering, University of Wisconsin, Madison, WI 53706, USA
    Neuroreport 14:1861-5. 2003
    ..The selective expression of Ro52/SS-A in brain at the microvasculature may play a role in brain vascular involvement in autoimmune diseases...
  73. ncbi request reprint Gene therapy of the brain: the trans-vascular approach
    Felix Schlachetzki
    Department of Neurology, University of Regensburg, Germany
    Neurology 62:1275-81. 2004
    ..Global and reversible expression of therapeutic genes in the human brain without surgery and without viral vectors is now possible...
  74. ncbi request reprint Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology
    Toyofumi Suzuki
    College of Pharmacy, Nihon University, Chiba, Japan
    J Nucl Med 45:1766-75. 2004
    ....